i2E Managementi2E Managementi2E Managementi2E Management
  • About
  • Portfolio
  • Team
  • Funds
  • Investor Login

Selexys is a pharmaceutical company that developed a platform of Selectin Inhibition Technology consisting of therapies that target P-selectin glycoprotein ligand-1 (PSGL-1) and P-selectin to treat pain among those with sickle cell disease.

Year Founded: 2005

Year Partnered: 2009

Category: Biotech/Pharma

Fund: Accelerate, Oklahoma Seed Capital Fund  

   Acquired in 2017 by Novartis

  • Disclaimer & Disclosure

Oklahoma City Location

840 Research Parkway, Suite 250
OKC, OK 73104
PHONE 405/235-2305

Tulsa Location

618 E. Third Street, Suite 1
Tulsa, OK 74120
PHONE 918/582-5592

  • Disclaimer & Disclosure
Copyright 2021 i2E, Inc. | All Rights Reserved
  • About
  • Portfolio
  • Team
  • Funds
i2E Management